UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell reports (Cambridge), 2018-03, Vol.22 (11), p.2978-2994

2018

Link zum Volltext

Verfügbarkeit prüfen

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

Molecular cancer therapeutics, 2018-02, Vol.17 (2), p.521-531

2018

Link zum Volltext

Verfügbarkeit prüfen

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

Clinical cancer research, 2017-09, Vol.23 (18), p.5547-5560

2017

Link zum Volltext

Verfügbarkeit prüfen

Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster

Journal of Virology, 2012-11, Vol.86 (21), p.11558-11566

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Journal for immunotherapy of cancer, 2018-04, Vol.6 (1), p.31-14, Article 31

2018

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.45-45, Article 45

2018

Link zum Volltext

Verfügbarkeit prüfen

Structure and composition of the postsynaptic density during development

Journal of comparative neurology (1911), 2010-10, Vol.518 (20), p.4243-4260

2010

Link zum Volltext

Verfügbarkeit prüfen

Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor

Gan to kagaku ryoho, 2023-12, Vol.50 (12), p.1307

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Clinical cancer research, 2016-01, Vol.22 (2), p.301-309

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

Molecular cancer therapeutics, 2020-04, Vol.19 (4), p.988-998

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3632-3632

2018

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-02, Vol.12 (2), p.383-389

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A160-A160

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.583-583

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2730-2730

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4569: The CDK4/6 inhibitor abemaciclib synergizes with PD-L1 blockade to induce an immune inflamed tumor microenvironment through T cell and tumor cell intrinsic effects

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4569-4569

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract A24: Beta-klotho expression is associated with the antitumor activity of pan-FGFR inhibitor in human malignancies with FGF19 amplification

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A24-A24

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract C129: Antitumor efficacy and non-clinical safety of the high affinity anti-FGFR4 antibody H4: Implications for targeting the FGF19-FGFR4 axis in oncology

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C129-C129

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of the N- and C-lobes of calmodulin in the activation of Ca(2+)/calmodulin-dependent protein kinase II

Biochemistry (Easton), 2008-10, Vol.47 (40), p.10587

2008

Link zum Volltext

Verfügbarkeit prüfen

Role of the N- and C-Lobes of Calmodulin in the Activation of Ca 2+ /Calmodulin-Dependent Protein Kinase II

Biochemistry (Easton), 2008-10, Vol.47 (40), p.10587-10599

2008

Link zum Volltext

Verfügbarkeit prüfen

Role of the N- and C-Lobes of Calmodulin in the Activation of Ca2+/Calmodulin-Dependent Protein Kinase II

Biochemistry (Easton), 2008-10, Vol.47 (40), p.10587-10599

2008

Link zum Volltext

Verfügbarkeit prüfen

Les mecanismes cellulaires et moleculaires du remodelage synaptique impliquant la proteine kinase calcium-CaM dependante II

Forest, Amelie

2006

Link zum Volltext

Verfügbarkeit prüfen

Actions and Challenges Toward Building Equity, Diversity, and Inclusion in Arctic Marine Science: The Case of the Canadian Research Icebreaker CCGS Amundsen

Oceanography (Washington, D.C.), 2023-12, Vol.36 (4)

2023

Link zum Volltext

Verfügbarkeit prüfen

Disclosure of Diagnosis in Early Recognition of Psychosis

The journal of nervous and mental disease, 2017-10, Vol.205 (10), p.757-761

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of first‐tier cell‐free DNA screening for common aneuploidies with conventional publically funded screening

Prenatal diagnosis, 2017-12, Vol.37 (12), p.1238-1244

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(15)
Humans
(9)
Female
(8)
Animals
(7)
Oncology
(6)
Mice
(5)
Adult
(4)
Monoclonal Antibodies
(4)
Cancer
(3)
Male
(3)
Antibodies
(2)
Antibodies, Monoclonal - Pharmacology
(2)
Antigens
(2)
Binding Sites
(2)
Biochemistry
(2)
Biological And Medical Sciences
(2)
Biomarkers, Tumor - Metabolism
(2)
Calcium-Calmodulin-Dependent Protein Kinase Type 2 - Metabolism
(2)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Structure and composition of the postsynaptic density during development

Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

Abstract 4569: The CDK4/6 inhibitor abemaciclib synergizes with PD-L1 blockade to induce an immune inflamed tumor microenvironment through T cell and tumor cell intrinsic effects

Abstract A24: Beta-klotho expression is associated with the antitumor activity of pan-FGFR inhibitor in human malignancies with FGF19 amplification

Abstract C129: Antitumor efficacy and non-clinical safety of the high affinity anti-FGFR4 antibody H4: Implications for targeting the FGF19-FGFR4 axis in oncology

Role of the N- and C-lobes of calmodulin in the activation of Ca(2+)/calmodulin-dependent protein kinase II

Role of the N- and C-Lobes of Calmodulin in the Activation of Ca 2+ /Calmodulin-Dependent Protein Kinase II

Role of the N- and C-Lobes of Calmodulin in the Activation of Ca2+/Calmodulin-Dependent Protein Kinase II

Les mecanismes cellulaires et moleculaires du remodelage synaptique impliquant la proteine kinase calcium-CaM dependante II

Actions and Challenges Toward Building Equity, Diversity, and Inclusion in Arctic Marine Science: The Case of the Canadian Research Icebreaker CCGS Amundsen

Disclosure of Diagnosis in Early Recognition of Psychosis

Comparison of first‐tier cell‐free DNA screening for common aneuploidies with conventional publically funded screening

Suchergebnisse filtern